JP5355582B2 - ベンゾジアゼピン化合物及び医薬組成物 - Google Patents

ベンゾジアゼピン化合物及び医薬組成物 Download PDF

Info

Publication number
JP5355582B2
JP5355582B2 JP2010533351A JP2010533351A JP5355582B2 JP 5355582 B2 JP5355582 B2 JP 5355582B2 JP 2010533351 A JP2010533351 A JP 2010533351A JP 2010533351 A JP2010533351 A JP 2010533351A JP 5355582 B2 JP5355582 B2 JP 5355582B2
Authority
JP
Japan
Prior art keywords
group
ethyl
pyridin
diazepine
trimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010533351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011512324A (ja
JP2011512324A5 (enExample
Inventor
邦生 大島
孝 押山
伸一 平良
康宏 校條
北斗 山邉
修二 松村
昌孝 植田
康雄 古賀
国憲 田井
直 中山
利幸 小野川
賢司 辻前
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP2010533351A priority Critical patent/JP5355582B2/ja
Publication of JP2011512324A publication Critical patent/JP2011512324A/ja
Publication of JP2011512324A5 publication Critical patent/JP2011512324A5/ja
Application granted granted Critical
Publication of JP5355582B2 publication Critical patent/JP5355582B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010533351A 2008-02-22 2009-02-20 ベンゾジアゼピン化合物及び医薬組成物 Expired - Fee Related JP5355582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010533351A JP5355582B2 (ja) 2008-02-22 2009-02-20 ベンゾジアゼピン化合物及び医薬組成物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2008041296 2008-02-22
JP2008041296 2008-02-22
JP2008227368 2008-09-04
JP2008227368 2008-09-04
JP2010533351A JP5355582B2 (ja) 2008-02-22 2009-02-20 ベンゾジアゼピン化合物及び医薬組成物
PCT/JP2009/053623 WO2009104819A1 (en) 2008-02-22 2009-02-20 Benzodiazepine compound and pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2011512324A JP2011512324A (ja) 2011-04-21
JP2011512324A5 JP2011512324A5 (enExample) 2013-08-29
JP5355582B2 true JP5355582B2 (ja) 2013-11-27

Family

ID=40600203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533351A Expired - Fee Related JP5355582B2 (ja) 2008-02-22 2009-02-20 ベンゾジアゼピン化合物及び医薬組成物

Country Status (26)

Country Link
US (2) US8338406B2 (enExample)
EP (1) EP2254873B1 (enExample)
JP (1) JP5355582B2 (enExample)
KR (1) KR101332948B1 (enExample)
CN (2) CN101952259B (enExample)
AR (1) AR070449A1 (enExample)
AU (1) AU2009216079B2 (enExample)
BR (1) BRPI0908132A2 (enExample)
CA (1) CA2715872A1 (enExample)
CO (1) CO6300950A2 (enExample)
CY (1) CY1115220T1 (enExample)
DK (1) DK2254873T3 (enExample)
ES (1) ES2494366T3 (enExample)
HR (1) HRP20140796T1 (enExample)
IL (1) IL207276A (enExample)
MX (1) MX2010009269A (enExample)
MY (1) MY156226A (enExample)
NZ (1) NZ587157A (enExample)
PL (1) PL2254873T3 (enExample)
PT (1) PT2254873E (enExample)
RU (1) RU2496775C2 (enExample)
SI (1) SI2254873T1 (enExample)
TW (1) TWI413522B (enExample)
UA (1) UA103018C2 (enExample)
WO (1) WO2009104819A1 (enExample)
ZA (1) ZA201005469B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101952259B (zh) 2008-02-22 2013-07-03 大塚制药株式会社 苯并二氮杂*化合物及药物组合物
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
WO2011021676A1 (ja) 2009-08-21 2011-02-24 大塚製薬株式会社 ベンゾ[b][1,4]ジアゼピン-2,4-ジオン化合物の製造方法
JP2012184225A (ja) * 2011-02-18 2012-09-27 Otsuka Pharmaceut Co Ltd 医薬組成物
JP6240063B2 (ja) 2011-04-28 2017-11-29 ザ ブロード インスティテュート, インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2780344A1 (en) 2011-11-15 2014-09-24 Xention Limited Thieno [2, 3 - c]pyrazoles for use as potassium channel inhibitors
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
WO2014018979A1 (en) 2012-07-27 2014-01-30 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA038455B1 (ru) * 2016-10-26 2021-08-31 Новартис Аг Новые производные нафтиридинона и их применение в лечении аритмии
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
HUE067265T2 (hu) 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
CN112135610A (zh) 2018-01-12 2020-12-25 KDAc治疗股份有限公司 用于治疗癌症的选择性组蛋白去乙酰酶3(hdac3)抑制剂及免疫治疗剂的组合
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133056A (en) 1961-05-15 1964-05-12 May & Baker Ltd N-phenylpiperazine derivatives of tetrahydrobenzodiazepines
US4001408A (en) 1966-12-14 1977-01-04 Roussel-Uclaf Substituted heterocyclic compounds, processes and composition including those
US3984398A (en) 1966-12-14 1976-10-05 Roussel-Uclaf 1,5-Benzodiazepine-2,4-diones
BE707667A (enExample) 1966-12-14 1968-06-07
JPH0296133A (ja) * 1988-10-01 1990-04-06 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
BR9200951A (pt) 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
US5691331A (en) * 1995-06-07 1997-11-25 Merck & Co., Inc. N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides
US5700797A (en) 1995-06-07 1997-12-23 Merck & Co, Inc. N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides
GB0008179D0 (en) 2000-04-05 2000-05-24 Glaxo Group Ltd Chemical process
AU6895000A (en) 1999-08-09 2001-03-05 Merck & Co., Inc. Antiarrhythmic compounds
HRP20040415A2 (en) * 2001-11-13 2005-04-30 3-Dimensional Pharmaceuticals Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CA2511214C (en) 2002-12-20 2012-12-18 Tularik, Inc. Asthma and allergic inflammation modulators
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CN101952259B (zh) 2008-02-22 2013-07-03 大塚制药株式会社 苯并二氮杂*化合物及药物组合物

Also Published As

Publication number Publication date
AU2009216079A1 (en) 2009-08-27
AU2009216079B2 (en) 2013-08-22
MY156226A (en) 2016-01-29
AR070449A1 (es) 2010-04-07
CN103554088A (zh) 2014-02-05
RU2010138928A (ru) 2012-03-27
BRPI0908132A2 (pt) 2015-08-04
CA2715872A1 (en) 2009-08-27
RU2496775C2 (ru) 2013-10-27
EP2254873B1 (en) 2014-06-04
HRP20140796T1 (hr) 2014-10-24
CY1115220T1 (el) 2017-01-04
PL2254873T3 (pl) 2014-10-31
ZA201005469B (en) 2011-11-30
IL207276A0 (en) 2010-12-30
US20130040941A1 (en) 2013-02-14
TW200940067A (en) 2009-10-01
CN103554088B (zh) 2016-02-24
JP2011512324A (ja) 2011-04-21
MX2010009269A (es) 2010-09-14
US8664217B2 (en) 2014-03-04
HK1145461A1 (en) 2011-04-21
CO6300950A2 (es) 2011-07-21
US8338406B2 (en) 2012-12-25
IL207276A (en) 2014-11-30
CN101952259B (zh) 2013-07-03
CN101952259A (zh) 2011-01-19
TWI413522B (zh) 2013-11-01
ES2494366T3 (es) 2014-09-15
PT2254873E (pt) 2014-08-29
NZ587157A (en) 2012-05-25
US20100331317A1 (en) 2010-12-30
DK2254873T3 (da) 2014-06-30
KR101332948B1 (ko) 2014-01-17
KR20100124781A (ko) 2010-11-29
UA103018C2 (uk) 2013-09-10
SI2254873T1 (sl) 2014-07-31
EP2254873A1 (en) 2010-12-01
WO2009104819A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
JP5355582B2 (ja) ベンゾジアゼピン化合物及び医薬組成物
JP5769700B2 (ja) 窒素含有化合物及び医薬組成物
CN107072985B (zh) 治疗性抑制化合物
US9518064B2 (en) Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
CN106459042A (zh) 抗纤维化吡啶酮类
JP2012184225A (ja) 医薬組成物
JP2007522142A (ja) Ikk3に対して活性を有するベンゾイミダゾール置換チオフェン誘導体
JP5669481B2 (ja) 医薬組成物
HK40016947A (en) Anti-fibrotic pyridinones
HK40016947B (en) Anti-fibrotic pyridinones
HK1145461B (en) Benzodiazepine compound and pharmaceutical composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130827

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees